Methomol500 mg

Methomol 500 mg is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of Methomol 500 mg has not been clearly identified, but may be related to its sedative properties. Methomol 500 mg does not directly relax tense skeletal muscles in man

Methomol 500 mg 500 mg: Initial dosage: 1500 mg (3 tablets) q.i.d. Maintenance dosage: 2 tablets q.i.d. Methomol 500 mg 750 mg: Initial dosage: 1500 mg (2 tablets) q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

Methomol 500 mg may inhibit the effect of pyridostigmine bromide. Therefore, Methomol 500 mg should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Methomol 500 mg is contraindicated in patients hypersensitive to Methomol 500 mg or to any of the tablet components.

Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headacheCardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitisDigestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomitingHemic and lymphatic system: LeukopeniaImmune system: Hypersensitivity reactionsNervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigoSkin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

Patients should be cautioned that Methomol 500 mg may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because Methomol 500 mg may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.Since Methomol 500 mg may possess a general CNS depressant effect, patients receiving Methomol 500 mg should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methomol 500 mg has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to Methomol 500 mg. Therefore, Methomol 500 mg should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards

Limited information is available on the acute toxicity of Methomol 500 mg. Overdose of Methomol 500 mg is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of Methomol 500 mg alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

Store at controlled room temperature, between 20°C and 25°C

Centrally acting Skeletal Muscle Relaxants

Methomol 500 mg is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methomol 500 mg's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.The mechanism of action of Methomol 500 mg in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pregnancy Category C. Animal reproduction studies have not been conducted with Methomol 500 mg. It is also not known whether Methomol 500 mg can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methomol 500 mg should be given to a pregnant woman only if clearly needed.Safe use of Methomol 500 mg has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to Methomol 500 mg. Therefore, Methomol 500 mg should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazardsNursing Mothers: Methomol 500 mg and/or its metabolites are excreted in the milk of dogs; however, it is not known whether Methomol 500 mg or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methomol 500 mg  is administered to a nursing woman.

Pediatric Use: Safety and effectiveness of Methomol 500 mg in pediatric patients below the age of 16 have not been established.